# N-Acetyl-Ser-Asp-Lys-Pro TFA

**MedChemExpress** 

HY-P0266A		
C <sub>22</sub> H <sub>34</sub> F <sub>3</sub> N <sub>5</sub> O <sub>11</sub>		
601.53		
Ac-Ser-Asp-Lys-Pro		
Ac-SDKP		
Angiotensin-converting Enzyme (ACE)		
Metabolic Enzyme/Protease		
Sealed storage, away from moisture		
Powder	-80°C	2 years
	-20°C	1 year
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)		
	HY-P0266A C <sub>22</sub> H <sub>34</sub> F <sub>3</sub> N <sub>5</sub> O 601.53 Ac-Ser-Asp-I Ac-SDKP Angiotensin Metabolic En Sealed stora Powder	HY-P0266A C <sub>22</sub> H <sub>34</sub> F <sub>3</sub> N <sub>5</sub> O <sub>11</sub> 601.53 Ac-Ser-Asp-Lys-Pro Ac-SDKP Angiotensin-convert Metabolic Enzyme/P Sealed storage, away Powder -80°C -20°C * In solvent : -80°C, 6

## **BIOLOGICAL ACTIVITY**

Description	N-Acetyl-Ser-Asp-Lys-Pro (TFA), an endogenous tetrapeptide secreted by bone marrow, is a specific substrate for the N- terminal site of ACE.
In Vitro	N-Acetyl-Ser-Asp-Lys-Pro is degraded specifically by ACE, and its plasma level rises substantially during ACE inhibitor therapy. Flow cytometry of rat cardiac fibroblasts treated with N-Acetyl-Ser-Asp-Lys-Pro shows significant inhibition of the progression of cells from G0/G1 phase to S phase of the cell cycle. Moreover, phosphorylation and nuclear translocation of Smad2 is decreased in cardiac fibroblasts treated with N-Acetyl-Ser-Asp-Lys-Pro <sup>[1]</sup> . N-acetyl-seryl-aspartyl-lysyl-proline appears to exert this function by blocking the action of a stem cell-specific proliferation stimulator and acts selectively on quiescent progenitors <sup>[2]</sup> . N-Acetyl-Ser-Asp-Lys-Pro inhibits collagenase expression and activation is associated with increased expression of TIMP-1 and TIMP-2. N-Acetyl-Ser-Asp-Lys-Pro normalizes the IL-1β-mediated increase in MMP-2 and MMP-9 activities and MMP-13 expression <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	N-Acetyl-Ser-Asp-Lys-Pro prevents hypertension-induced inflammatory cell infiltration, collagen deposition, nephrin downregulation and albuminuria, which could lead to renoprotection in hypertensive mice <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### REFERENCES

[1]. Rousseau A, et al. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specificsubstrate of the N-terminal active site of human angiotensinconverting enzyme. J Biol Chem. 1995 Feb 24;270(8):3656-61.

[2]. Pokharel S, et al. N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension. 2002 Aug;40(2):155-61.

[3]. Rhaleb NE, et al. N-acetyl-Ser-Asp-Lys-Pro inhibits interleukin-1β-mediated matrix metalloproteinase activation in cardiac fibroblasts. Pflugers Arch. 2013 Oct;465(10):1487-95.

[4]. Rhaleb NE, et al. Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice. J Hypertens. 2011 Feb;29(2):330-8.

# Product Data Sheet

0 0

 $H_2N$ 

`ŅН<sup>О</sup>

ОН

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA